« Previous
Next »
Titles
- Racial and ethnic health disparities1
- Racial and ethnic inequities in health care coverage and access: 2013–20191
- Rare diseases: Although limited, available evidence suggests medical and other costs can be substantial : report to congressional committees1
- Rate of uninsured infants and toddlers on the rise1
- Rationalizing a Medicare buy-in policy for adults ages 50 to 64 that builds on the ACA1
- Reaching the remaining uninsured: an evidence review on outreach & enrollment1
- Recognition and withdrawal of voluntary consensus standards: guidance for industry and Food and Drug Administration staff1
- Recommendations for clinical laboratory improvement amendments of 1988 (CLIA) waiver applications for manufacturers of in vitro diagnostic devices: guidance for industry and Food and Drug Administration staff1
- Recommendations for dual 510(k) and CLIA waiver by application studies: guidance for industry and Food and Drug Administration staff1
- Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components1
- Recovery with limited progress: impact of California Proposition 209 on racial/ethnic diversity of California medical school matriculants, 1990 to 20191
- Redistribution of federal funding across states due to the financing of Medicaid and CHIP1
- Reducing private insurance hospital payments will require a lengthy phase-in period1
- Referencing approved drug products in ANDA submissions2
- Registered nurse and advanced practice registered nurse workforce and education in California1
- Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use : guidance for industry and Food and Drug Administration staff1
- Regulatory considerations for microneedling products: guidance for industry and Food and Drug Administration staff1
- Reimbursing FQHCs for telehealth post-COVID-19 pandemic: Medi-Cal’s options1
- Remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities during the COVID-19 public health emergency1
- Remote patient monitoring in the safety net: what payers and providers need to know1